A Phase 4 interventional study of Tirbanibulin 2.5 mg ointment in Actinic Keratosis, sponsored by Almirall, S.A.. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Almirall, S.A. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Keratosis, Actinic by Almirall, S.A. — none open to participants now, 1 under way, none of them phase 3. Keratosis, Actinic · Almirall, S.A..
Among the 14 studies in Keratosis, Actinic by Almirall, S.A., this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 4, and was the 13th registered.
343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.
Browse Keratosis, Actinic studies →None of the 14 studies in Keratosis, Actinic by Almirall, S.A. is open now. The open studies under Keratosis, Actinic, anywhere →
Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 334 is above the median of 60 across 295 interventional studies indexed under Keratosis, Actinic.
Median enrollment 307 across the 12 interventional studies, 155 across the 2 observational. Of the 13 that completed or were terminated, 7 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
Almirall, S.A. is the lead sponsor of 66 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 7 (78%) have results posted.
1 of the studies in Keratosis, Actinic by Almirall, S.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05387525Almirall, S.A.A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Keratosis, Actinic by Almirall, S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess treatment satisfaction on Day 57 in participants with Actinic Keratoses (AK) of the face or scalp following treatment with tirbanibulin ointment 1 percent (%) administered once daily for 5 consecutive days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Use of the following therapies and/or medications within 2 weeks prior to the Screening Visit:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will apply tirbanibulin ointment- topically at a dose of 2.5 mg once daily for 5 consecutive days- on the face or scalp.
Drug: Tirbanibulin 2.5 mg ointment
Participants will apply tirbanibulin 2.5 mg ointment topically for 5 consecutive days over 25 square centimeters (cm\^2) of the face or scalp.
Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Total Score of Each Components at Day 57
TSQM-9 was a 9-item clinically validated psychometric instrument developed from the TSQM 1.4. TSQM-9 measures participant satisfaction with the medication in 3 domains: Effectiveness, convenience, and global satisfaction. The scores were computed by adding items for each domain, i.e., 1 to 3 for effectiveness, 4 to 6 for convenience, and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) x 3 items = 18 for effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100, with higher scores indicating greater satisfaction for that domain. A positive change from baseline indicates improvement.
Time frame: At Day 57
Change From Baseline in Skindex-16 Questionnaire Symptoms Sub-Score at Day 57
Skindex-16 was used for participants to rate skin conditions that have occurred within the previous week. The Skindex-16 consisted of 16 items that were divided into three sub-scores: Symptoms (four items, range 0-24), Emotions (seven items, range 0-42), and Functioning (five items, range 0-30). Participant were asked to respond on how much their skin condition bothered them in the week prior to administration of the Skindex-16. Each item was scored on a scale ranged from 0 (never bothered) to 6 (always bothered), where higher score indicated continued/more botheration. Item scores are transformed to 0 to 100 scale, and domain scores are calculated as the average of the item scores comprising the domain. Net positive changes in respective subscale scoring indicates improvement in that particular quality of life assessment (i.e., Symptoms, Emotions, Functioning), while net negative changes in scoring indicates decrease in that particular quality of life assessment.
Time frame: Baseline, Day 57
Percentage of Participants With Organoleptic Properties of Tirbanibulin Assessed on a Likert Scale at Day 8
Likert scale was an instrument used to measure the individual's degree of agreement and disagreement with a variety of statements about some attitude, options, or their feelings. In this study, the product's organoleptic properties are evaluated with Likert scale. The questionnaire was built with questions related to the product's characteristics namely appearance, color, convenience, texture, smell, and the feelings experienced during drug application. The Likert scale offers 7 possible answers, from "totally agree",' In agreement", "Somewhat agree", "Neither agree nor disagree", "Something in disagreement", "In disagreement" and "totally in disagreement".
Time frame: At Day 8
Treatment Satisfaction Questionnaire for Medication Version 1.4 (TSQM 1.4) Components Scores at Day 57
TSQM 1.4 was a 14-item robust instrument that psychometrically evaluates the treatment satisfaction of the administered medication. The instrument is designed with 4 scales consisting of 14 questions. These 14 questions were derived from an original set of 55 questions extracted from exhaustive literature review and treatment groups through multistep iterative process. The 4 scales focused on effectiveness (questions: 1-3), side effects (questions: 4-8), convenience (questions: 9-11), global satisfaction (questions:12-14). Global Satisfaction- Question 12 scored as 1 (not at all confident) to 5 (extremely confident); question 13 scored as 1 (not at all certain) to 5 (extremely certain); and question 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction.
Time frame: At Day 57
Percentage of Patients Who Answered Expert Panel Questionnaire (EPQ) (Question 1 to Question 9) at Day 57
An expert panel on consensus developed a questionnaire directed to patients consisting of 9 simple items using a qualitative modified delphi method. Expert panel agreed to ask 9 specific items; 1: Overall appearance of the skin (much worse to much improved); 2: Treatment satisfaction of skin looks (extremely dissatisfied to extremely satisfied); 3: Treatment satisfaction of skin texture (extremely dissatisfied to extremely satisfied); 4: Duration of skin reactions (much shorter to much longer); 5: rate the severity of skin reactions (much better to much worse); 6: impact on your daily activities due to skin reactions (much better to much worse); 7: rate the convenience/ease of use (much better to much worse); 8: rate your overall satisfaction (much better to much worse); 9: You need to be retreated for AK, how likely are you to consider tirbanibulin (very unlikely to very likely).
Time frame: At Day 57
Percentage of Physician Who Answered Expert Panel Questionnaire (EPQ) (Question 1 to Question 10) at Day 57
An expert panel on consensus developed a questionnaire directed to physicians consisting of 10 simple items using a qualitative modified delphi method. Expert panel agreed to ask 10 specific items-1: Overall appearance of the skin (much worse to much improved); 2: Treatment satisfaction of skin looks (extremely dissatisfied to extremely satisfied); 3: Treatment satisfaction of skin texture (extremely dissatisfied to extremely satisfied); 4: Duration of skin reactions (much shorter to much longer); 5: rate the severity of skin reactions (much better to much worse); 6: impact on patient's daily activities due to skin reactions (much better to much worse); 7: rate the convenience/ease of use (much better to much worse); 8: rate your overall satisfaction (much better to much worse); 9: patient needs to be retreated for AK, how likely to consider tirbanibulin (very unlikely to very likely);10: severity of skin photodamage in the original AK treated area (absent to severe).
Time frame: At Day 57
Percentage of Participants With Complete (100%) Clearance of All Lesions Within the Application Area at Day 57
Complete clearance of all AK lesions within the application area, is defined as a reduction from baseline in the number of lesions = 100% at Day 57. Percentage of participants with complete clearance with a reduction of 100% (i.e., clearance percentage = 100% from Baseline) in the number of lesions within the application area were reported.
Time frame: At Day 57
Percentage of Participants With Partial Clearance (Reduction of at Least >=75% to <100%) of All Lesions Within the Application Area at Day 57
Participants with partial clearance were patients with a reduction of \>=75% (i.e., clearance percentage \<=-75% from Baseline) to \<100% in the number of lesions within the application area at final visit.
Time frame: At Day 57
Percent Change From Baseline in Mean Number of Old and New AK Lesions at Day 57
Percent change from baseline in number of old and new AK lesions at Day 57 was reported. Number of lesions at Day 57 was calculated considering both old and new lesions, as: N lesions at Baseline - N lesions at Day 57/ N lesions at Baseline \* 100%.
Time frame: At Day 57
Percentage of Participants by Olsen Characterization at Baseline and Day 57
The lesions in the identified treatment area will be classified based on Olsen characterization. Classification of AK lesions according to Olsen grade of baseline lesions: Olsen Grade I: Early AK appear as single or few, differently sized, rough, blurred, less visible than palpable, red, rough spots or very flat, non-edged plaques which reach into the reddish color; Olsen grade II: describes advanced AK as clearly visible and palpable, flat, and irregularly raised, with sharp or blurred boundaries, red, rough keratinized surface. If the surface is more strongly keratinized, the AK can also be white, yellow, or light brown. After scratching effects, a black or blue-black shade may appear; Olsen grade III: denotes "late" AK that have existed for a longer period of time and are firmly anchored on the lower surface, with an irregular, humpy surface, also wart-like and of different colors (white, brown, black).
Time frame: Baseline (Day 0) and Day 57
Percentage of Participants Who Performed Line-field Confocal Optical Coherence Tomography (LC-OCT) for Clinical and Sub Clinical Lesions Assessment at Each Timepoint
LC-OCT was a novel non-invasive imaging technique that enables in vivo visualization of the skin. It has been used for diagnosing and monitoring the treatment of skin disorders, including actinic keratosis. The use of LC-OCT in AK treatment progression allows for lesion classification based on histological features without the need for a biopsy. The histopathology of the skin was evaluated based on the estimated atypia score at cellular level of the LC-OCT images of clinical and subclinical lesions. Percentage of participants who performed LC-OCT for clinical and subclinical lesions assessment at each timepoint were reported.
Time frame: Baseline, Day 8, Day 15, Day 29, and Day 57
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Severity of TEAEs
An adverse event (AE) is as any untoward medical occurrence associated with the use of an intervention in humans after providing written informed consent for participation in the study until the end of study visit, whether considered intervention-related or not. A TEAE is defined as an AE with an onset that occurs after receiving study drug. Severity of TEAEs is graded as follows: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
Time frame: From start of study administration up to Day 57
This study was conducted at 37 sites in Europe (7 in Italy and 30 in Spain) from 20 January 2023 to 19 January 2024.
| Milestone | Tirbanibulin 2.5 mg |
|---|---|
| Started | 334 |
| Evaluable population | 328 |
| Line-field confocal optical coherence tomography (lc-oct) population | 12 |
| Safety population | 334 |
| Completed | 327 |
| Not completed | 7 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Protocol deviation | 3 |
| Withdrew: Withdrawal by subject | 1 |
TSQM-9 was a 9-item clinically validated psychometric instrument developed from the TSQM 1.4. TSQM-9 measures participant satisfaction with the medication in 3 domains: Effectiveness, convenience, and global satisfaction. The scores were computed by adding items for each domain, i.e., 1 to 3 for effectiveness, 4 to 6 for convenience, and 7 to 9 for global satisfaction. The lowest possible score (1 for each item and 3 for all 3 subscales) was subtracted from the composite score and divided by the greatest possible score range. The greatest range was (7-1) x 3 items = 18 for effectiveness and convenience, and (5-1) x 3 items = 12 for global satisfaction. This provided a transformed score between 0 and 1 that was then multiplied by 100. TSQM-9 domain scores range from 0 to 100, with higher scores indicating greater satisfaction for that domain. A positive change from baseline indicates improvement.
| score on a scale | Tirbanibulin 2.5 mg |
|---|---|
| Effectiveness Total Score Value | 73.64 (71.28 to 76.01) |
| Convenience Total Score Value | 82.81 (81.28 to 84.34) |
| Global Satisfaction Total Score Value | 76.94 (74.89 to 78.99) |
Skindex-16 was used for participants to rate skin conditions that have occurred within the previous week. The Skindex-16 consisted of 16 items that were divided into three sub-scores: Symptoms (four items, range 0-24), Emotions (seven items, range 0-42), and Functioning (five items, range 0-30). Participant were asked to respond on how much their skin condition bothered them in the week prior to administration of the Skindex-16. Each item was scored on a scale ranged from 0 (never bothered) to 6 (always bothered), where higher score indicated continued/more botheration. Item scores are transformed to 0 to 100 scale, and domain scores are calculated as the average of the item scores comprising the domain. Net positive changes in respective subscale scoring indicates improvement in that particular quality of life assessment (i.e., Symptoms, Emotions, Functioning), while net negative changes in scoring indicates decrease in that particular quality of life assessment.
| score on a scale | Tirbanibulin 2.5 mg |
|---|---|
| Symptoms Sub-Score: Change at Day 57 | -10.49 (-12.55 to -8.44) |
| Emotions Sub-Score: Change at Day 57 | -11.56 (-13.56 to -9.55) |
| Functioning Sub-Score: Change at Day 57 | -2.49 (-3.98 to -1.00) |
Likert scale was an instrument used to measure the individual's degree of agreement and disagreement with a variety of statements about some attitude, options, or their feelings. In this study, the product's organoleptic properties are evaluated with Likert scale. The questionnaire was built with questions related to the product's characteristics namely appearance, color, convenience, texture, smell, and the feelings experienced during drug application. The Likert scale offers 7 possible answers, from "totally agree",' In agreement", "Somewhat agree", "Neither agree nor disagree", "Something in disagreement", "In disagreement" and "totally in disagreement".
| Percentage of participants | Tirbanibulin 2.5 mg |
|---|---|
| The general appearance of the product is good: Totally agree | 52.60 (43.75 to 61.34) |
| The general appearance of the product is good: In agreement | 38.23 (29.91 to 47.04) |
| The general appearance of the product is good: Somewhat agree | 3.06 (0.85 to 7.22) |
| The general appearance of the product is good: Neither agree nor disagree | 5.20 (2.11 to 10.15) |
| The general appearance of the product is good: Something in disagreement | 0.31 (0.00 to 2.76) |
| The general appearance of the product is good: In disagreement | 0.61 (0.00 to 3.36) |
| The general appearance of the product is good: Totally in disagreement | 0 (0 to 0) |
| The overall assessment of the product is very satisfactory: Totally agree | 36.70 (27.64 to 46.33) |
| The overall assessment of the product is very satisfactory: In agreement | 38.53 (29.35 to 48.21) |
| The overall assessment of the product is very satisfactory: Somewhat agree | 8.26 (3.75 to 14.57) |
| The overall assessment of the product is very satisfactory: Neither agree nor disagree | 10.40 (5.28 to 17.23) |
| The overall assessment of the product is very satisfactory: Something in disagreement | 1.53 (0.00 to 5.18) |
| The overall assessment of the product is very satisfactory: In disagreement | 3.36 (0.74 to 8.01) |
| The overall assessment of the product is very satisfactory: Totally in disagreement | 1.22 (0.00 to 4.66) |
| I would recommend the product: Totally agree | 34.86 (25.95 to 44.43) |
| I would recommend the product: In agreement | 33.64 (24.83 to 43.15) |
| I would recommend the product: Somewhat agree | 5.81 (2.13 to 11.40) |
| I would recommend the product: Neither agree nor disagree | 18.04 (11.25 to 26.22) |
| I would recommend the product: Something in disagreement | 1.22 (0.00 to 4.66) |
| I would recommend the product: In disagreement | 3.06 (0.59 to 7.56) |
| I would recommend the product: Totally in disagreement | 3.36 (0.74 to 8.01) |
| The color of the product is nice: Totally agree | 36.70 (29.37 to 44.55) |
| The color of the product is nice: In agreement | 36.09 (28.80 to 43.92) |
| The color of the product is nice: Somewhat agree | 5.81 (2.90 to 10.47) |
| The color of the product is nice: Neither agree nor disagree | 20.80 (14.96 to 27.79) |
| The color of the product is nice: Something in disagreement | 0 (0 to 0) |
| The color of the product is nice: In disagreement | 0.61 (0.02 to 3.17) |
| The color of the product is nice: Totally in disagreement | 0 (0 to 0) |
| The texture of the product is nice: Totally agree | 48.93 (40.14 to 57.76) |
| The texture of the product is nice: In agreement | 40.37 (31.92 to 49.21) |
| The texture of the product is nice: Somewhat agree | 5.20 (2.11 to 10.15) |
| The texture of the product is nice: Neither agree nor disagree | 4.28 (1.54 to 8.93) |
| The texture of the product is nice: Something in disagreement | 0.61 (0.00 to 3.36) |
| The texture of the product is nice: In disagreement | 0.61 (0.00 to 3.36) |
| The texture of the product is nice: Totally in disagreement | 0 (0 to 0) |
| The texture of the product is watery: Totally agree | 12.84 (7.12 to 20.18) |
| The texture of the product is watery: In agreement | 18.65 (11.76 to 26.91) |
| The texture of the product is watery: Somewhat agree | 9.79 (4.83 to 16.48) |
| The texture of the product is watery: Neither agree nor disagree | 15.90 (9.52 to 23.76) |
| The texture of the product is watery: Something in disagreement | 8.26 (3.75 to 14.57) |
| The texture of the product is watery: In disagreement | 19.88 (12.77 to 28.29) |
| The texture of the product is watery: Totally in disagreement | 14.68 (8.54 to 22.34) |
| The texture of the product is oily: Totally agree | 11.31 (5.96 to 18.35) |
| The texture of the product is oily: In agreement | 15.90 (9.52 to 23.76) |
| The texture of the product is oily: Somewhat agree | 9.48 (4.61 to 16.10) |
| The texture of the product is oily: Neither agree nor disagree | 16.82 (10.26 to 24.82) |
| The texture of the product is oily: Something in disagreement | 6.73 (2.72 to 12.61) |
| The texture of the product is oily: In disagreement | 20.49 (13.28 to 28.97) |
| The texture of the product is oily: Totally in disagreement | 19.27 (12.26 to 27.60) |
| The texture of the product is creamy: Totally agree | 40.06 (30.78 to 49.77) |
| The texture of the product is creamy: In agreement | 41.28 (31.93 to 51.01) |
| The texture of the product is creamy: Somewhat agree | 7.03 (2.92 to 13.00) |
| The texture of the product is creamy: Neither agree nor disagree | 7.34 (3.13 to 13.40) |
| The texture of the product is creamy: Something in disagreement | 1.53 (0.00 to 5.18) |
| The texture of the product is creamy: In disagreement | 1.83 (0.08 to 5.68) |
| The texture of the product is creamy: Totally in disagreement | 0.92 (0.00 to 4.11) |
| The skin was greasy after applying the treatment: Totally agree | 12.84 (7.12 to 20.18) |
| The skin was greasy after applying the treatment: In agreement | 25.08 (17.20 to 34.03) |
| The skin was greasy after applying the treatment: Somewhat agree | 14.68 (8.54 to 22.34) |
| The skin was greasy after applying the treatment: Neither agree nor disagree | 8.56 (3.96 to 14.95) |
| The skin was greasy after applying the treatment: Something in disagreement | 3.98 (1.06 to 8.89) |
| The skin was greasy after applying the treatment: In disagreement | 17.13 (10.50 to 25.17) |
| The skin was greasy after applying the treatment: Totally in disagreement | 17.74 (11.00 to 25.87) |
| The smell of the product is pleasant: Totally agree | 23.85 (16.14 to 32.70) |
| The smell of the product is pleasant: In agreement | 23.55 (15.88 to 32.36) |
| The smell of the product is pleasant: Somewhat agree | 7.65 (3.33 to 13.79) |
| The smell of the product is pleasant: Neither agree nor disagree | 42.51 (33.09 to 52.25) |
| The smell of the product is pleasant: Something in disagreement | 0.61 (0.00 to 3.53) |
| The smell of the product is pleasant: In disagreement | 0.92 (0.00 to 4.11) |
| The smell of the product is pleasant: Totally in disagreement | 0.92 (0.00 to 4.11) |
| The product feels pleasant on the skin: Totally agree | 27.22 (19.07 to 36.35) |
| The product feels pleasant on the skin: In agreement | 30.28 (21.79 to 39.61) |
| The product feels pleasant on the skin: Somewhat agree | 10.70 (5.50 to 17.60) |
| The product feels pleasant on the skin: Neither agree nor disagree | 21.10 (13.80 to 29.66) |
| The product feels pleasant on the skin: Something in disagreement | 1.83 (0.08 to 5.68) |
| The product feels pleasant on the skin: In disagreement | 5.50 (1.95 to 10.99) |
| The product feels pleasant on the skin: Totally in disagreement | 3.36 (0.74 to 8.01) |
| The feel of the product on the skin is refreshing: Totally agree | 18.35 (11.50 to 26.56) |
| The feel of the product on the skin is refreshing: In agreement | 20.80 (13.54 to 29.32) |
| The feel of the product on the skin is refreshing: Somewhat agree | 11.31 (5.96 to 18.35) |
| The feel of the product on the skin is refreshing: Neither agree nor disagree | 22.94 (15.36 to 31.69) |
| The feel of the product on the skin is refreshing: Something in disagreement | 5.81 (2.13 to 11.40) |
| The feel of the product on the skin is refreshing: In disagreement | 10.09 (5.06 to 16.86) |
| The feel of the product on the skin is refreshing: Totally in disagreement | 10.70 (5.50 to 17.60) |
| The product offers a protective feeling: Totally agree | 20.80 (13.54 to 29.32) |
| The product offers a protective feeling: In agreement | 25.38 (17.47 to 34.36) |
| The product offers a protective feeling: Somewhat agree | 9.48 (4.61 to 16.10) |
| The product offers a protective feeling: Neither agree nor disagree | 30.28 (21.79 to 39.61) |
| The product offers a protective feeling: Something in disagreement | 3.06 (0.59 to 7.56) |
| The product offers a protective feeling: In disagreement | 5.81 (2.13 to 11.40) |
| The product offers a protective feeling: Totally in disagreement | 5.20 (1.76 to 10.58) |
| The product is easy to apply: Totally agree | 66.36 (56.85 to 75.17) |
| The product is easy to apply: In agreement | 27.22 (19.07 to 36.35) |
| The product is easy to apply: Somewhat agree | 3.67 (0.89 to 8.45) |
| The product is easy to apply: Neither agree nor disagree | 0.92 (0.00 to 4.11) |
| The product is easy to apply: Something in disagreement | 0.92 (0.00 to 4.11) |
| The product is easy to apply: In disagreement | 0.31 (0.00 to 2.90) |
| The product is easy to apply: Totally in disagreement | 0.61 (0.00 to 3.53) |
| The product can be distributed evenly and easily: Totally agree | 64.53 (55.79 to 72.66) |
| The product can be distributed evenly and easily: In agreement | 29.05 (21.48 to 37.50) |
| The product can be distributed evenly and easily: Somewhat agree | 4.28 (1.54 to 8.93) |
| The product can be distributed evenly and easily: Neither agree nor disagree | 0.61 (0.00 to 3.36) |
| The product can be distributed evenly and easily: Something in disagreement | 0.92 (0.00 to 3.91) |
| The product can be distributed evenly and easily: In disagreement | 0.61 (0.00 to 3.36) |
| The product can be distributed evenly and easily: Totally in disagreement | 0 (0 to 0) |
| Product remains on application area, without spreading to neighboring areas: Totally agree | 57.19 (47.44 to 66.62) |
| Product remains on application area, without spreading to neighboring areas: In agreement | 29.97 (21.52 to 39.29) |
| Product remains on application area, without spreading to neighboring areas: Somewhat agree | 6.12 (2.33 to 11.81) |
| Product remains on application area, without spreading to neighboring areas: Neither agree/ disagree | 2.75 (0.44 to 7.11) |
| Product remains on application area without spreading to neighboring areas:Something in disagreement | 2.14 (0.19 to 6.17) |
| Product remains on application area, without spreading to neighboring areas: In disagreement | 0.61 (0.00 to 3.53) |
| Product remains on application area, without spreading to neighboring areas: Totally in disagreement | 1.22 (0.00 to 4.66) |
| The product packaging is practical: Totally agree | 50.76 (41.06 to 60.43) |
| The product packaging is practical: In agreement | 33.94 (25.11 to 43.47) |
| The product packaging is practical: Somewhat agree | 6.12 (2.33 to 11.81) |
| The product packaging is practical: Neither agree nor disagree | 3.06 (0.59 to 7.56) |
| The product packaging is practical: Something in disagreement | 2.14 (0.19 to 6.17) |
| The product packaging is practical: In disagreement | 3.36 (0.74 to 8.01) |
| The product packaging is practical: Totally in disagreement | 0.61 (0.00 to 3.53) |
TSQM 1.4 was a 14-item robust instrument that psychometrically evaluates the treatment satisfaction of the administered medication. The instrument is designed with 4 scales consisting of 14 questions. These 14 questions were derived from an original set of 55 questions extracted from exhaustive literature review and treatment groups through multistep iterative process. The 4 scales focused on effectiveness (questions: 1-3), side effects (questions: 4-8), convenience (questions: 9-11), global satisfaction (questions:12-14). Global Satisfaction- Question 12 scored as 1 (not at all confident) to 5 (extremely confident); question 13 scored as 1 (not at all certain) to 5 (extremely certain); and question 14 scored as 1 (extremely dissatisfied) to 7 (extremely satisfied). The scores of the domain were added together and an algorithm was used to create a score of 0 to 100. Higher scores indicated greater satisfaction.
| score on a scale | Tirbanibulin 2.5 mg |
|---|---|
| Effectiveness score value at Day 57 | 73.64 (71.28 to 76.01) |
| Convenience score value at Day 57 | 82.81 (81.28 to 84.34) |
| Side Effects score value at Day 57 | 97.47 (96.59 to 98.34) |
| Global satisfaction score value at Day 57 | 76.94 (74.89 to 78.99) |
An expert panel on consensus developed a questionnaire directed to patients consisting of 9 simple items using a qualitative modified delphi method. Expert panel agreed to ask 9 specific items; 1: Overall appearance of the skin (much worse to much improved); 2: Treatment satisfaction of skin looks (extremely dissatisfied to extremely satisfied); 3: Treatment satisfaction of skin texture (extremely dissatisfied to extremely satisfied); 4: Duration of skin reactions (much shorter to much longer); 5: rate the severity of skin reactions (much better to much worse); 6: impact on your daily activities due to skin reactions (much better to much worse); 7: rate the convenience/ease of use (much better to much worse); 8: rate your overall satisfaction (much better to much worse); 9: You need to be retreated for AK, how likely are you to consider tirbanibulin (very unlikely to very likely).
| Percentage of patients | Tirbanibulin 2.5 mg |
|---|---|
| Overall appearance of the skin: Much worse | 0.31 (0.00 to 2.68) |
| Overall appearance of the skin: Somewhat worse | 0.31 (0.00 to 2.68) |
| Overall appearance of the skin: No change | 6.92 (3.66 to 11.94) |
| Overall appearance of the skin: Somewhat improved | 24.84 (18.45 to 32.27) |
| Overall appearance of the skin: Much improved | 67.61 (59.78 to 74.72) |
| Treatment satisfaction of skin looks: Extremely Dissatisfied | 0 (0 to 0) |
| Treatment satisfaction of skin looks: Very Dissatisfied | 0.63 (0.00 to 3.45) |
| Treatment satisfaction of skin looks: Dissatisfied | 2.83 (0.71 to 6.97) |
| Treatment satisfaction of skin looks: Somewhat Satisfied | 7.23 (3.43 to 12.86) |
| Treatment satisfaction of skin looks: Satisfied | 25.79 (18.47 to 34.14) |
| Treatment satisfaction of skin looks: Very Satisfied | 30.19 (22.40 to 38.82) |
| Treatment satisfaction of skin looks: Extremely Satisfied | 33.33 (25.26 to 42.12) |
| Treatment satisfaction of skin texture: Extremely Dissatisfied | 0 (0 to 0) |
| Treatment satisfaction of skin texture: Very Dissatisfied | 1.25 (0.05 to 4.51) |
| Treatment satisfaction of skin texture: Dissatisfied | 2.80 (0.70 to 6.91) |
| Treatment satisfaction of skin texture: Somewhat Satisfied | 7.17 (3.40 to 12.75) |
| Treatment satisfaction of skin texture: Satisfied | 30.84 (23.03 to 39.47) |
| Treatment satisfaction of skin texture: Very Satisfied | 27.73 (20.23 to 36.17) |
| Treatment satisfaction of skin texture: Extremely Satisfied | 30.22 (22.46 to 38.81) |
| Duration of skin reactions: Much shorter | 44.62 (34.53 to 55.09) |
| Duration of skin reactions: Somewhat shorter | 23.66 (15.73 to 33.40) |
| Duration of skin reactions: Same | 18.82 (11.74 to 28.04) |
| Duration of skin reactions: Somewhat longer | 9.14 (4.42 to 16.67) |
| Duration of skin reactions: Much longer | 3.76 (1.11 to 9.60) |
| Rate the severity of skin reactions: Much better | 51.34 (40.98 to 61.60) |
| Rate the severity of skin reactions: Somewhat better | 21.93 (14.30 to 31.47) |
| Rate the severity of skin reactions: Same | 16.58 (9.97 to 25.48) |
| Rate the severity of skin reactions: Somewhat worse | 8.02 (3.68 to 15.24) |
| Rate the severity of skin reactions: Much worse | 2.14 (0.37 to 7.18) |
| Impact on your daily activities due to skin reactions: Much better | 49.74 (39.48 to 60.00) |
| Impact on your daily activities due to skin reactions: Somewhat better | 13.76 (7.81 to 22.16) |
| Impact on your daily activities due to skin reactions: Same | 31.75 (22.79 to 41.94) |
| Impact on your daily activities due to skin reactions: Somewhat worse | 3.70 (1.09 to 9.46) |
| Impact on your daily activities due to skin reactions: Much worse | 1.06 (0.04 to 5.39) |
| Rate the convenience/ease of use: Much better | 57.97 (48.02 to 67.42) |
| Rate the convenience/ease of use: Somewhat better | 19.81 (12.86 to 28.63) |
| Rate the convenience/ease of use: Same | 19.81 (12.86 to 28.63) |
| Rate the convenience/ease of use: Somewhat worse | 1.93 (0.34 to 6.51) |
| Rate the convenience/ease of use: Much worse | 0.48 (0.00 to 4.08) |
| Rate your overall satisfaction: Much better | 60.29 (50.40 to 69.54) |
| Rate your overall satisfaction: Somewhat better | 21.53 (14.32 to 30.49) |
| Rate your overall satisfaction: Same | 13.40 (7.77 to 21.28) |
| Rate your overall satisfaction: Somewhat worse | 3.83 (1.24 to 9.26) |
| Rate your overall satisfaction: Much worse | 0.96 (0.04 to 4.89) |
| You need to be retreated for AK, how likely to consider tirbanibulin: Very unlikely | 3.66 (1.49 to 7.67) |
| You need to be retreated for AK, how likely to consider tirbanibulin: Somewhat unlikely | 2.44 (0.78 to 5.98) |
| You need to be retreated for AK, how likely to consider tirbanibulin: Neutral | 7.62 (4.21 to 12.72) |
| You need to be retreated for AK, how likely to consider tirbanibulin: Somewhat likely | 18.60 (13.08 to 25.37) |
| You need to be retreated for AK, how likely to consider tirbanibulin: Very likely | 67.68 (59.98 to 74.69) |
An expert panel on consensus developed a questionnaire directed to physicians consisting of 10 simple items using a qualitative modified delphi method. Expert panel agreed to ask 10 specific items-1: Overall appearance of the skin (much worse to much improved); 2: Treatment satisfaction of skin looks (extremely dissatisfied to extremely satisfied); 3: Treatment satisfaction of skin texture (extremely dissatisfied to extremely satisfied); 4: Duration of skin reactions (much shorter to much longer); 5: rate the severity of skin reactions (much better to much worse); 6: impact on patient's daily activities due to skin reactions (much better to much worse); 7: rate the convenience/ease of use (much better to much worse); 8: rate your overall satisfaction (much better to much worse); 9: patient needs to be retreated for AK, how likely to consider tirbanibulin (very unlikely to very likely);10: severity of skin photodamage in the original AK treated area (absent to severe).
| Percentage of physician | Tirbanibulin 2.5 mg |
|---|---|
| Overall appearance of the skin:Much worse | 1.23 (0.21 to 4.19) |
| Overall appearance of the skin: Somewhat worse | 1.23 (0.21 to 4.19) |
| Overall appearance of the skin: No change | 1.23 (0.21 to 4.19) |
| Overall appearance of the skin: Somewhat improved | 21.78 (15.81 to 28.87) |
| Overall appearance of the skin: Much improved | 74.54 (67.17 to 80.93) |
| Treatment satisfaction of skin looks: Extremely Dissatisfied | 0.31 (0.00 to 2.93) |
| Treatment satisfaction of skin looks: Very Dissatisfied | 0.31 (0.00 to 2.93) |
| Treatment satisfaction of skin looks: Dissatisfied | 0.31 (0.00 to 2.93) |
| Treatment satisfaction of skin looks: Somewhat Satisfied | 6.79 (2.75 to 12.72) |
| Treatment satisfaction of skin looks: Satisfied | 25.31 (17.37 to 34.33) |
| Treatment satisfaction of skin looks: Very Satisfied | 31.48 (22.84 to 40.93) |
| Treatment satisfaction of skin looks: Extremely Satisfied | 35.49 (26.49 to 45.13) |
| Treatment satisfaction of skin texture: Extremely Dissatisfied | 0.31 (0.00 to 2.92) |
| Treatment satisfaction of skin texture: Very Dissatisfied | 0.31 (0.00 to 2.92) |
| Treatment satisfaction of skin texture: Dissatisfied | 0.92 (0.00 to 4.14) |
| Treatment satisfaction of skin texture: Somewhat Satisfied | 6.77 (2.74 to 12.68) |
| Treatment satisfaction of skin texture: Satisfied | 27.69 (19.47 to 36.89) |
| Treatment satisfaction of skin texture: Very Satisfied | 32.92 (24.16 to 42.43) |
| Treatment satisfaction of skin texture: Extremely Satisfied | 31.08 (22.49 to 40.49) |
| Duration of skin reactions: Much shorter | 60.09 (50.51 to 69.08) |
| Duration of skin reactions: Somewhat shorter | 27.35 (19.54 to 36.48) |
| Duration of skin reactions: Same | 8.52 (4.29 to 15.14) |
| Duration of skin reactions: Somewhat longer | 3.14 (0.92 to 8.06) |
| Duration of skin reactions: Much longer | 0.90 (0.03 to 4.60) |
| Rate the severity of skin reactions: Much better | 64.86 (55.36 to 73.15) |
| Rate the severity of skin reactions: Somewhat better | 22.07 (14.96 to 30.80) |
| Rate the severity of skin reactions: Same | 9.01 (4.63 to 15.76) |
| Rate the severity of skin reactions: Somewhat worse | 3.60 (1.16 to 8.74) |
| Rate the severity of skin reactions: Much worse | 0.45 (0.00 to 3.81) |
| Impact on patient's daily activities due to skin reactions: Much better | 59.81 (50.04 to 69.00) |
| Impact on patient's daily activities due to skin reactions: Somewhat better | 19.63 (12.81 to 28.27) |
| Impact on patient's daily activities due to skin reactions: Same | 19.63 (12.81 to 28.27) |
| Impact on patient's daily activities due to skin reactions: Somewhat worse | 0.47 (0.00 to 3.95) |
| Impact on patient's daily activities due to skin reactions: Much worse | 0.47 (0.00 to 3.95) |
| Rate the convenience/ease of use: Much better | 65.78 (57.55 to 73.16) |
| Rate the convenience/ease of use: Somewhat better | 25.33 (18.82 to 33.17) |
| Rate the convenience/ease of use: Same | 5.33 (2.66 to 10.42) |
| Rate the convenience/ease of use: Somewhat worse | 3.56 (1.52 to 8.10) |
| Rate the convenience/ease of use: Much worse | 0 (0 to 0) |
| Rate your overall satisfaction: Much better | 50.66 (41.25 to 60.03) |
| Rate your overall satisfaction: Somewhat better | 37.00 (28.30 to 46.45) |
| Rate your overall satisfaction: Same | 11.01 (6.14 to 18.11) |
| Rate your overall satisfaction: Somewhat worse | 0.88 (0.03 to 4.52) |
| Rate your overall satisfaction: Much worse | 0.44 (0.00 to 3.73) |
| Patient needs to be retreated for AK, how likely to consider tirbanibulin: Very unlikely | 3.68 (1.50 to 7.71) |
| Patient needs to be retreated for AK, how likely to consider tirbanibulin: Somewhat unlikely | 1.53 (0.34 to 4.66) |
| Patient needs to be retreated for AK, how likely to consider tirbanibulin: Neutral | 7.67 (4.24 to 12.79) |
| Patient needs to be retreated for AK, how likely to consider tirbanibulin: Somewhat likely | 23.01 (16.89 to 30.20) |
| Patient needs to be retreated for AK, how likely to consider tirbanibulin: Very likely | 64.11 (56.26 to 71.39) |
| Severity of skin photodamage in the original AK treated area: Absent | 24.85 (19.38 to 31.26) |
| Severity of skin photodamage in the original AK treated area: Mild | 46.63 (39.85 to 53.53) |
| Severity of skin photodamage in the original AK treated area: Moderate | 27.61 (21.89 to 34.17) |
| Severity of skin photodamage in the original AK treated area: Severe | 0.92 (0.24 to 3.44) |
Complete clearance of all AK lesions within the application area, is defined as a reduction from baseline in the number of lesions = 100% at Day 57. Percentage of participants with complete clearance with a reduction of 100% (i.e., clearance percentage = 100% from Baseline) in the number of lesions within the application area were reported.
| Percentage of participants | Tirbanibulin 2.5 mg |
|---|---|
| Percentage of Participants With Complete (100%) Clearance of All Lesions Within the Application Area at Day 57 | 54.27 (48.71 to 59.75) |
Participants with partial clearance were patients with a reduction of \>=75% (i.e., clearance percentage \<=-75% from Baseline) to \<100% in the number of lesions within the application area at final visit.
| Percentage of participants | Tirbanibulin 2.5 mg |
|---|---|
| Percentage of Participants With Partial Clearance (Reduction of at Least >=75% to <100%) of All Lesions Within the Application Area at Day 57 | 22.56 (18.15 to 27.47) |
Percent change from baseline in number of old and new AK lesions at Day 57 was reported. Number of lesions at Day 57 was calculated considering both old and new lesions, as: N lesions at Baseline - N lesions at Day 57/ N lesions at Baseline \* 100%.
| Percent change | Tirbanibulin 2.5 mg |
|---|---|
| Percent Change From Baseline in Mean Number of Old and New AK Lesions at Day 57 | -82.22 ± 26.367 |
The lesions in the identified treatment area will be classified based on Olsen characterization. Classification of AK lesions according to Olsen grade of baseline lesions: Olsen Grade I: Early AK appear as single or few, differently sized, rough, blurred, less visible than palpable, red, rough spots or very flat, non-edged plaques which reach into the reddish color; Olsen grade II: describes advanced AK as clearly visible and palpable, flat, and irregularly raised, with sharp or blurred boundaries, red, rough keratinized surface. If the surface is more strongly keratinized, the AK can also be white, yellow, or light brown. After scratching effects, a black or blue-black shade may appear; Olsen grade III: denotes "late" AK that have existed for a longer period of time and are firmly anchored on the lower surface, with an irregular, humpy surface, also wart-like and of different colors (white, brown, black).
| Percentage of participants | Tirbanibulin 2.5 mg |
|---|---|
| Olsen Grade I: Baseline | 62.80 (54.95 to 70.15) |
| Olsen Grade I: Day 57 | 39.33 (30.95 to 48.15) |
| Olsen Grade II: Baseline | 8.84 (5.12 to 14.19) |
| Olsen Grade II: Day 57 | 3.66 (1.18 to 8.06) |
| Olsen Grade III: Baseline | 0.0 (0.00 to 0.00) |
| Olsen Grade III: Day 57 | 0.30 (0.00 to 2.75) |
LC-OCT was a novel non-invasive imaging technique that enables in vivo visualization of the skin. It has been used for diagnosing and monitoring the treatment of skin disorders, including actinic keratosis. The use of LC-OCT in AK treatment progression allows for lesion classification based on histological features without the need for a biopsy. The histopathology of the skin was evaluated based on the estimated atypia score at cellular level of the LC-OCT images of clinical and subclinical lesions. Percentage of participants who performed LC-OCT for clinical and subclinical lesions assessment at each timepoint were reported.
| Percentage of participants | Tirbanibulin 2.5 mg |
|---|---|
| At Baseline | 100.00 |
| At Day 8 | 91.67 |
| At Day 15 | 91.67 |
| At Day 29 | 91.67 |
| At Day 57 | 100.00 |
An adverse event (AE) is as any untoward medical occurrence associated with the use of an intervention in humans after providing written informed consent for participation in the study until the end of study visit, whether considered intervention-related or not. A TEAE is defined as an AE with an onset that occurs after receiving study drug. Severity of TEAEs is graded as follows: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living. Grade 4 Life-threatening consequences; urgent intervention indicated.
| Participants | Tirbanibulin 2.5 mg |
|---|---|
| Participants with TEAEs | 153 |
| Severity of TEAEs: Grade 1 | 132 |
| Severity of TEAEs: Grade 2 | 17 |
| Severity of TEAEs: Grade 3 | 3 |
| Severity of TEAEs: Grade 4 | 1 |
Collected over From start of study administration up to Day 57. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tirbanibulin 2.5 mg | 0/334 (0%) | 0/334 (0%) | 153/334 (45.8%) |
| Event | Tirbanibulin 2.5 mg |
|---|---|
| PruritusSkin and subcutaneous tissue disorders | 92/334 |
| PainGeneral disorders | 31/334 |
| Burning sensationGeneral disorders | 17/334 |
| HeadacheNervous system disorders | 13/334 |
| FatigueGeneral disorders | 6/334 |
| HypersensitivityImmune system disorders | 6/334 |
| BlisterSkin and subcutaneous tissue disorders | 5/334 |
| Thermal burnSkin and subcutaneous tissue disorders | 4/334 |
| Application site painGeneral disorders | 3/334 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/334 |
Full analysis set (FAS) population included all participants who signed the informed consent form and applied at least one dose of tirbanibulin.
| Age, Continuous(years) | Tirbanibulin 2.5 mg |
|---|---|
| Mean | 74.9 ± 8.51 |
| Sex: Female, Male(Participants) | Tirbanibulin 2.5 mg |
|---|---|
| Female | 56 |
| Male | 278 |
| Race/Ethnicity, Customized(Participants) | Tirbanibulin 2.5 mg |
|---|---|
| Race: Caucasian | 334 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2023 to primary completion in Jan 2024, 11 months.
Results were first posted in Feb 2025, 1 year 1 month after primary completion.
Of 19 phase 4 interventional studies under Keratosis, Actinic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 30. This study's 11 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirbanibulin